INT20251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 1990
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 12
Disease Relevance 5.33
Pain Relevance 1.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Alox5) nuclear envelope (Alox5) oxidoreductase activity (Alox5)
nucleus (Alox5) cytoplasm (Alox5)
Anatomy Link Frequency
macrophage 1
liver 1
brain 1
Uterine 1
microglia 1
Alox5 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 137 99.24 Very High Very High Very High
metalloproteinase 1 98.80 Very High Very High Very High
rheumatoid arthritis 1 96.96 Very High Very High Very High
Pain 1 96.08 Very High Very High Very High
ischemia 126 95.28 Very High Very High Very High
fibrosis 1 95.16 Very High Very High Very High
cINOD 13 93.48 High High
Bioavailability 24 90.48 High High
aspirin 1 87.80 High High
Dismenorea 1 85.60 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 186 99.24 Very High Very High Very High
Brain Hemorrhage 48 99.16 Very High Very High Very High
Disease 19 98.72 Very High Very High Very High
Asthma 1 97.96 Very High Very High Very High
Increased Venous Pressure Under Development 7 97.64 Very High Very High Very High
Injury 135 97.20 Very High Very High Very High
Rheumatoid Arthritis 1 96.96 Very High Very High Very High
Pain 1 96.08 Very High Very High Very High
Cancer 1 95.84 Very High Very High Very High
Cirrhosis 1 95.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The 5-lipoxygenase (5-LOX) pathway has been associated with a variety of inflammatory diseases including asthma, atherosclerosis, rheumatoid arthritis, pain, cancer and liver fibrosis.
5-LOX Binding (associated) of in liver associated with pain, cirrhosis, rheumatoid arthritis, increased venous pressure under development, disease, fibrosis, asthma, inflammation and cancer
1) Confidence 0.32 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18295198 Disease Relevance 0.84 Pain Relevance 0.27
There was also evidence of an interaction between the COX-2 -765 G>C and ALOX5 -1700 G>A genotypes (P(interaction) = 0.07).
ALOX5 Binding (interaction) of
2) Confidence 0.26 Published 2006 Journal Cancer Epidemiol. Biomarkers Prev. Section Abstract Doc Link 16537708 Disease Relevance 0.95 Pain Relevance 0.48
The concentrations of these compounds that inhibit lipoxygenase were similar to those required to inhibit cyclooxygenase.
lipoxygenase Binding (compounds) of
3) Confidence 0.26 Published 1990 Journal Dent Jpn (Tokyo) Section Abstract Doc Link 2129162 Disease Relevance 0 Pain Relevance 0.10
Uterine mRNA expressions of matrix metalloproteinase-1 (MMP-1), which degrades collagens, and of lysyl oxidase (LO), which is necessary for the formation of intra- and inter-molecular cross-links of collagen, were examined by quantitative RT-PCR.
LO Binding (cross-links) of in Uterine associated with metalloproteinase
4) Confidence 0.13 Published 2004 Journal J. Endocrinol. Section Abstract Doc Link 14765986 Disease Relevance 0.25 Pain Relevance 0.14
BW-B 70C demonstrated a neuroprotective role through inhibition of both 5-LOX and NF-?
5-LOX Neg (inhibition) Binding (inhibition) of
5) Confidence 0.12 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.56 Pain Relevance 0.29
In the treatment group, the rats were given 5-LOX inhibitor, dissolved in sterile DMSO (15 ?
5-LOX Binding (inhibitor) of
6) Confidence 0.12 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.53 Pain Relevance 0.17
Treatment with 5-LOX inhibitors improves brain infarction and neurological score after IR injury
5-LOX Binding (Treatment) of in brain associated with brain hemorrhage and injury
7) Confidence 0.12 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.40 Pain Relevance 0.06
The expression also co-localized in the microglia/macrophage, as seen by merging the 5-LOX and microglia/macrophage antigen RCA-1 (Fig. 2i).
5-LOX Binding (merging) of in microglia
8) Confidence 0.12 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.38 Pain Relevance 0
B activation by direct interaction with 5-LOX remain to be investigated.
5-LOX Binding (interaction) of
9) Confidence 0.12 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.89 Pain Relevance 0.27
The expression also co-localized in the microglia/macrophage, as seen by merging the 5-LOX and microglia/macrophage antigen RCA-1 (Fig. 2i).
5-LOX Binding (merging) of in macrophage
10) Confidence 0.04 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.38 Pain Relevance 0
In 3-oxo-TA-challenged PMNs, the mitogen-activated protein kinase kinase (MEK)-1/2 inhibitor PD098059 abolished 5-LO product formation, along with inhibition of MEK-1/2 phosphorylation and 5-LO translocation.
5-LO Binding (formation) of
11) Confidence 0.02 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11455013 Disease Relevance 0.06 Pain Relevance 0.06
In our attempt to characterize the stimulating constituents, we identified the tetracyclic triterpene 3-oxo-tirucallic acid (3-oxo-TA), which, in the range from 2.5 to 15 microM, enhanced 5-LO product formation in ionophore-challenged polymorphonuclear cells (PMNs) (e.g., from 1981 +/- 177 to 3042 +/- 208 pmol at 10 microM 3-oxo-TA), and initiated Ca(2+) mobilization, MEK-1/2 phosphorylation, 5-LO translocation, and 5-LO product formation in resting cells (534 +/- 394 pmol/5 x 10(6) PMNs).
5-LO Binding (formation) of
12) Confidence 0.02 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11455013 Disease Relevance 0.09 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox